^
Association details:
| Biomarker: | BCR-ABL1 H396P |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib Is a Pan-BCR-ABL Kinase Inhibitor: MD Simulations and SIE Study
Excerpt:
The remaining three mutants (M351T, H396P and M244V) in ABL kinase structure are located away from ponatinib binding site but are inhibited by ponatinib.
DOI:
https://dx.doi.org/10.1371%2Fjournal.pone.0078556
